Iconic Crocin Pain Relief to get a relaunch
New Delhi: To strengthen its position in the pain relief category, GSK Consumer Healthcare moved to re-launch its iconic brancd Crocin Pain Relief which is especially designed to offer relief from headaches. Delivering targeted pain relief, its formula contains clinically proven ingredients, that act at the center of pain.
As part of the launch, the brand has released three relatable video films that bring alive the condition and its impact on peoples' lives. The launch is being supported with an awareness campaign across television and digital platforms. The awareness plan also includes an extensive outreach to Heath care Professionals and chemists to create awareness and education on the condition and the product benefits.
As per company's website, Crocin Pain Relief provides targeted pain relief. It provide symptomatic relief from mild to moderate pain e.g from headache, migraine, toothache and musculoskeletal pain. Its formula contains clinically proven ingredients paracetamol and caffeine. It acts at the center of pain.
Naveed Ahmed, Area Marketing Director, Wellness, GSK Consumer Healthcare said, "In today's times when everyone has multiple priorities, dealing with a headache should never come in the way of everyday life. Keeping this in mind, GSK Consumer Healthcare is excited to re-launch Crocin Pain Relief, a solution that is specially designed as an effective yet gentle product for everyday headaches.
Read Also: GSK Pharma reports Q2 profit at Rs 503 crore
Crocin has been a trusted household healthcare name for decades and enjoys strong equity with consumers. It is India's largest selling analgesic brand with a range of variants in both solid and liquid format. More than 25 million tablets of Crocin are sold each day in India. That's nearly 25 tablets every second around the clock. GSK markets five varients of Crocin namely Crocin Advance, Crocin 650 Mg, Crocin Pain Relief, Crocin Cold & Flu and Crocin's Children Range (Crocin 120, Crocin 140, Croin Drops).
Read Also: GSK lifts annual profit forecast after third quarter beat on vaccines strength
Garima joined Medical Dialogues in the year 2017 and is currently working as a Senior Editor. She looks after all the Healthcare news pertaining to Medico-legal cases, MCI/DCI decisions, Medical Education issues, government policies as well as all the news and updates concerning Medical and Dental Colleges in India. She is a graduate from Delhi University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd